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Abstract
Aims/hypothesis Upon tissue injury, peripheral sensory neu-
rons release nociceptive factors (e.g. substance P [SP]), which
exert local and systemic actions including the recruitment of
bone marrow (BM)-derived haematopoietic stem and progen-
itor cells (HSPCs) endowed with paracrine pro-angiogenic
properties. We herein explore whether diabetic neuropathy
interferes with these phenomena.
Methods We first investigated the presence of sensory neu-
ropathy in the BM of patients with type 2 diabetes by immu-
nohistochemistry and morphometry analyses of nerve size and
density and assessment of SP release by ELISA. We next
analysed the association of sensory neuropathy with altered
HSPC release under ischaemia or following direct stimulation
with granulocyte colony-stimulating factor (G-CSF). BM and
circulating HSPCs expressing the neurokinin 1 receptor
(NK1R), which is the main SP receptor, were measured by
flow cytometry. We finally assessed whether an altered mod-
ulation of SP secretion interferes with the mobilisation and
homing of NK1R-HSPCs in a mouse model of type 2 diabetes
after limb ischaemia (LI).
Results Nociceptive fibres were reduced in the BM of patients
and mice with type 2 diabetes. Patients with neuropathy
showed a remarkable reduction in NK1R-HSPC mobilisation
under ischaemia or upon G-CSF stimulation. Following LI,
diabetic mice manifested an altered SP gradient between BM,
peripheral blood and limb muscles, accompanied by a
depressed recruitment of NK1R-HSPCs to the ischaemic site.
Conclusions/interpretation Sensory neuropathy translates
into defective liberation and homing of reparative HSPCs.
Nociceptors may represent a new target for treatment of dia-
betic complications.
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G-CSF Granulocyte colony-stimulating factor
HSPC Haematopoietic stem and progenitor cell
LI Limb ischaemia
NK1R Neurokinin 1 receptor
PB Peripheral blood
SP Substance P
T2DM-N Type 2 diabetes mellitus with peripheral
neuropathy
T2DM-NI Type 2 diabetes mellitus with peripheral
neuropathy and CLI
T2DM-U Uncomplicated type 2 diabetes mellitus
Introduction
Diabetic patients manifest a defective release of haematopoietic
stem and progenitor cells (HSPCs) following tissue injury,
ischaemia or stimulation by granulocyte colony-stimulating
factor (G-CSF), a condition referred to as diabetic stem cell
mobilopathy [1]. This feature is emerging as a clinically rele-
vant pathology associated with increased risk of vascular com-
plications [1, 2]. Structural and functional abnormalities of the
bone marrow (BM) microenvironment might contribute to
these phenomena [3]. A better mechanistic understanding
might help in the introduction of new strategies to counteract
the consequences of mobilopathy in diabetic patients.
New exciting evidence indicates that an intact nociceptive
system is crucial for the recruitment of regenerative cells from
the circulation to ischaemic tissues. We have recently report-
ed that, in otherwise healthy mice, ischaemia triggers differ-
ential nociceptor responses in peripheral tissues and BM,
thereby generating a gradient of neuropeptide substance
P (SP)/neurokinin 1 that favours the release and homing of
HSPCs expressing the NK1 receptor (NK1R), which is the
main receptor for SP [4]. Recruitment of NK1R-HSPCs to the
ischaemic site helps tissue healing through paracrine stimula-
tion of reparative angiogenesis. The crucial contribution of
this mechanism to post-ischaemic recovery is highlighted by
the observation that BM reconstitution with Nk1r-knockout
(also known as Tacr1-knockout) HSPCs results in depressed
HSPC mobilisation, delayed blood-flow recovery and reduced
neovascularisation after ischaemia. [4] Importantly, this mech-
anism participates in modulation of the HSPCs’mobilisation in
humans. In fact, patients with acute myocardial infarction show
high circulating and cardiac levels of SP and NK1R-HSPCs
whereas these phenomena are abrogated in infarcted patients
with a denervated transplanted heart [4].
Diabetic neuropathy is a common and disabling manifes-
tation of diabetes mellitus and often overlaps with vascular
complications [5, 6]. Direct neuronal damage caused by
hyperglycaemia and downregulation of neurotrophic factors
concurs in the pathogenesis of diabetic neuropathy [7, 8].
Sensory neuropathy is a typical form of peripheral neuropathy
characterised by an altered perception of noxious stimuli
[9–12]. From a functional standpoint, it manifests as an inabil-
ity of neurons to produce proper amounts of neuropeptides,
like SP and calcitonin-gene related peptide, in response to
tissue injury. Altered nociception facilitates foot ulcers caused
by pressure or trauma and abrogates warning symptoms dur-
ing a heart attack. These consequences are mainly attributed to
failure of peripheral healing mechanisms. It is not yet known
whether extension of sensory neuropathy to the BMmay con-
tribute to altered stem cell release. Additionally, direct stimu-
lation of BM-HSPC liberation by G-CSF is frequently associ-
ated with intense bone pain. Although peripheral sympathetic
nerves reportedly participate in G-CSF-induced mobilisation
[13, 14], the contribution of a dysfunctional nociceptive
signalling in diabetic BM unresponsiveness to G-CSF has
not been addressed so far.
This study investigates whether sensory neuropathy
extends to the BM of patients and mice with diabetes and
plays a role in stem cell mobilopathy. Results indicate for
the first time that diabetic sensory neuropathy contributes
towards hindrance of cellular mechanisms of tissue repair.
Methods
Details of methodology and inclusion/exclusion criteria are
provided in the electronic supplementary material (ESM)
Methods.
Human studies We conducted four distinct studies to verify
the presence of sensory neuropathy in BM and its association
with defective HSPC release under ischaemia or following
direct stimulation.
We carried out two cross-sectional studies. The first was an
observational pathology study assessing the presence of neu-
ropathy in the BM of patients with type 2 diabetes (either
uncomplicated or complicated with foot lesions) and its asso-
ciation with alteration in the abundance of antigenically defined
HSPC subpopulations. Consecutive patients with type 2 diabe-
tes and non-diabetic controls were recruited at Santa Maria di
Ca’ Foncello Hospital (Treviso), IRCCS MultiMedica (Milan)
and the University Hospital of Parma, under Ethics Committee
approval and after obtaining informed consent (ESM Tables 1
and 2). Non-diabetic individuals were enrolled among those
referred for hip replacement surgery or diagnostic BM exami-
nation to exclude a haematological disease. The patients with
type 2 diabetes were subdivided into three groups: (1)
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uncomplicated (T2DM-U), (2) with peripheral neuropathy
(T2DM-N) and (3) with peripheral neuropathy and critical limb
ischaemia (CLI) (T2DM-NI). Peripheral neuropathy was de-
fined using the diabetic neurological index and neuropathy
disability score [9, 15] and autonomic neuropathy using the
criteria of the American Autonomic Society and the
American Academy of Neurology [16, 17]. CLI was diagnosed
based on TASC 2007 criteria [18].
The second cross-sectional study was aimed at confirming
the alteration of SP receptor NK1R expression on circulating
CD34+ HSPCs in an independent cohort of patients with type
2 diabetes referred to the Outpatient Clinic of the University
Hospital of Padova, under approval of the local ethics com-
mittee and after obtaining informed consent (ESM Table 3).
In addition, two intervention studies retrospectively veri-
fied the relationship between HSPCs mobilisation and
nociception. First, we re-analysed the results of a trial con-
ducted in 40 healthy volunteers, in which the primary end-
point was to determine the effect of subcutaneous pegylated
human recombinant G-CSF on the mobilisation of HSPCs [19].
Back pain and bone pain were given a score of 1, 2 or 3 for
mild, moderate or severe intensity, respectively. Duration of
pain in days was recorded. A final pain score was calculated
as intensity × duration. Patients were then divided into two
equal groups according to the median value of their pain score
and the absolute average change in CD34+ cells/ml before and
after G-CSF was calculated for each group. The placebo group
was used as a control for pain and change in CD34+ cell counts.
Finally, we re-analysed the results of a recent trial per-
formed at the University Hospital of Padova, the primary end-
point of which was to compare the CD34+ cell mobilisation
response to low-dose human recombinant G-CSF in non-
diabetic individuals and diabetic patients (NCT01102699)
[2, 20]. Changes in peripheral blood (PB) CD34+ cell count
and SP levels from baseline were computed according to the
presence or absence of G-CSF-induced pain (ESM Table 4).
Animal studies Experiments were performed in accordance
with the Guide for the Care and Use of Laboratory Animals
(The Institute of Laboratory Animal Resources, 1996) and with






































































































Fig. 1 Rarefaction and degeneration of sensory fibres in the BM of
patients with type 2 diabetes. (a) Representative micrographs and
quantification of neuronal fibres expressing the pan-neuronal marker
PGP9.5 (brown, indicated by arrowheads) (scale bar, 20 μm). Box and
whisker graphs illustrate the difference between non-diabetic individuals
(ND, black box, n=18) and patients with type 2 diabetes (n=24) classified
as T2DM-U (white box, n=4), T2DM-N (light grey box, n=5) or T2DM-NI
(dark grey box, n=15). *p<0.05 and **p<0.01 vs ND. (b) Representative
micrographs and quantification of neuronal fibres co-expressing PGP9.5
(brown) and SP (red) (scale bar, 20 μm). Box and whisker graphs
illustrate the difference between groups. *p<0.05 vs ND. (c) Micrographs
represent typical neuronal fibre features in non-diabetic individuals and
patients with type 2 diabetes mellitus (T2DM) (scale bar, 50 μm). Box
and whisker graphs illustrate neuronal fibre diameter in study groups.
*p<0.05, **p<0.01 and ***p<0.001 vs ND and †p<0.05 vs T2DM-U.
(d) Typical immunohistochemistry and immunofluorescence staining of
subsequent BM slides from the same patient with type 2 diabetes shows
infiltration of the perineurium by CD68+ macrophages. Lower panels are
magnifications of the fields delimited by red dotted squares, (scale bar,
20 μm)
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Office (Licence: 30/2811). As a model of type 2 diabetes, we
used 16-week-old male obese leptin-receptor homozygous mu-
tant BKS.Cg-Leprdb/Leprdb/OlaHsd (db/db) mice (Harlan,
Blackthorn,UK). Elevation of blood glucose starts at 4–8weeks
of age, followed by manifestation of neuropathy [21]. Age- and
sex-matched lean (BKS.Cg-m+/+Leprdb/OlaHsd) (db/+) mice
served as controls.
As a model of reparative neovascularisation, we applied
unilateral limb ischaemia (LI), induced by ligature of the left
femoral artery [22]. Mice were killed at 0, 3, 7, 14 or 21 days
after LI (n=5 mice per group) and PB and BM from tibias and
femurs were collected for analyses.
Analytical measurements ELISA kits were used to deter-
mine SP levels (Cayman Chemical, Ann Arbor, Michigan,
USA).
For flow cytometry experiments, whole blood was collect-
ed in tubes containing EDTA. BM cells were obtained by
flushing mouse femoral marrow. In human studies, marrow
was either sampled from the posterior iliac crest or collected
from bone remnants of hip surgery. Cells were also isolated by
enzymatic digestion from the adductor muscles of mice
undergoing LI. Quantification of antigenically defined cell
populations was conducted by flow cytometry (concentration
of antibodies is shown in ESM Table 5).
In the immunohistochemistry and immunofluorescence
studies, decalcified BM biopsies were embedded in paraffin
and sectioned at 2 μm. Sections were then incubated with
primary and secondary antibodies (ESM Table 5) following
standard procedures.
Statistical analysis Continuous variables were compared
among groups using ANOVA, with post hoc Student’s t test
after Bonferroni correction. Categorical variables were com-
pared using the χ2 test. The association between continuous
variables was evaluated using Pearson’s r coefficient. The
p values are two-sided and statistically significant when <0.05.
Multiple linear regression analyses were used to adjust for
clinical and demographical variables that resulted in an imbal-
ance between groups. Analyses were performed with Stata 12
(Stata Statistical Software, College Station, TX, USA) Graphs
were generated using GraphPad Prism 5 (GraphPad Software,
La Jolla, CA, USA).
Results
Pathology study showing the association of sensory neu-
ropathy and stem cell mobilopathy in patients with type 2
diabetes We first sought evidence of sensory neuropathy in
the BM of patients with type 2 diabetes by conducting an
analysis of neuronal fibre density on specimens collected from
iliac crest biopsies or bone left over from hip reconstructive
surgery. Since nerve density was similar in the two source
groups, data were pooled in the final analysis. By immunohis-
tochemistry, we recognised a striking decrease in the total
number of nerve fibres that express the general neuronal
marker PGP9.5 in the BM of diabetic patients with
neuropathic (T2DM-N) and neuropathic/ischaemic complica-
tions (T2DM-NI) (Fig. 1a, ANOVA p<0.001). This defect
extends to nociceptive fibres that co-express PGP9.5 and SP
(Fig. 1b, ANOVA p<0.01) and to tyrosine hydroxylase-
positive sympathetic fibres (ESM Fig. 1a, p<0.05 vs non-
diabetic controls). Additionally, in the BM of T2DM-N and
T2DM-NI patients, both PGP9.5-positive and SP-positive
nerve fibres showed a marked increase in diameter (Fig. 1c,
ANOVA p<0.0001 and p<0.01, respectively), as well as
vacuolisation and infiltration with CD68-positive macro-
phages (Fig. 1d). These degenerative/inflammatory features
were not observed in non-diabetic controls. This association




































Fig. 2 Type 2 diabetes alters the levels of SP in PB and BM. (a) Immu-
nostaining for SP in BM and graph showing SP levels in the BM of non-
diabetic individuals; positive SP-stained area (ASP) as a percentage of the
total area of sections (ATOT). (ND, n=7) and patients with type 2 diabetes
(n=4, each subgroup [see (b)]) (scale bar, 50 μm). (b) Bar graphs
(mean and SEM) showing quantitative analysis of immunoreactive SP
in the PB of non-diabetic controls (black bar, n=15) and patients with
type 2 diabetes classified as uncomplicated (T2DM-U, white bar, n=13)
or complicated by neuropathy (T2DM-N, light grey bar, n=35) or neu-
ropathy and CLI (T2DM-NI, dark grey bar, n=33). *p<0.05, **p<0.01
and ***p<0.001 for indicated comparisons
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was additionally confirmed in a multivariable analysis adjusted
by age, BMI, fasting glucose and HbA1c. Furthermore, neuro-
nal rarefaction was associated with reduction in BM capillary
density (ESM Fig. 1b), which identifies a distinct form of
microangiopathy we have described previously in animal
models and patients with diabetes [23, 24]. Furthermore, by
immunofluorescence microscopy, we detected a significant
reduction in SP expression in the BM of diabetic patients with
neuropathy (p<0.01 vs non-diabetic controls) but not in those
with superimposed CLI (Fig. 2a). In addition, SP levels were
remarkably reduced in the PB of neuropathic diabetic patients
with or without CLI (p<0.001 vs non-diabetic controls;
p<0.001 vs uncomplicated diabetes) (Fig. 2b).
Having documented the presence of structural and func-
tional nociceptive alterations in the BM of patients with type
2 diabetes, we next conducted immunofluorescence and flow
cytometry analyses of CD34+ HSPCs, which co-express the SP
receptor NK1R. Patients with complicated diabetes showed a
depletion of CD34+NK1R+HSPCs in their BM (Fig. 3a–d) and
PB (Fig. 3e–h). Mean fluorescence intensity analysis indicated
that NK1R was downregulated in cells from diabetic patients
(Fig. 3g). Furthermore, superimposed CLI failed to induce an
T2DM-N T2DM-NI
CD34 NK1 DAPI CD34 NK1 DAPI
CD34 NK1 DAPI CD34 NK1 DAPI
ND T2DM-U
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Fig. 3 Impaired release of
CD34+NK1R+ cells in patients




CD34+NK1R+ cells (scale bar,
20 μm). ND, non-diabetic.
Arrowheads show cells positive
for CD34 and NK1R markers.
(b–d) Bar graphs showing the
levels of CD34+ (b) and
CD34+NK1R+ cells (c) and
relative abundance of NK1R+
cells over total CD34+ cells
(d). Black bars, non-diabetic
(n=6); white bars, T2DM-U
(n=3); light grey bars, T2DM-N
(n=5); dark grey, T2DM-NI
(n=10). (e–g) Bar graphs
showing the abundance of
CD34+ (e) and NK1R+ cells on
total CD34+ cells (f) (p=0.06,
non-diabetic vs T2DM-NI) in
the PB of non-diabetic
individuals and patients with
type 2 diabetes, assessed by
flow cytometry (non-diabetic,
n=8; T2DM-U, n=5; T2DM-N,
n=12; T2DM-NI, n=11); the
NK1R mean fluorescence
intensity on CD34+ cells is
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increment in circulating CD34+NK1R+ HSPCs (Fig. 3e–h).
Altogether, these data indicate that sensory neuropathy is asso-
ciatedwith BMdepletion and altered release of a subpopulation
of HSPCs that is responsive to SP chemoattraction. In particu-
lar, the presence of ischaemia, which reportedly acts as a potent
stimulus for CD34+NK1R+ HSPC release [4], fails to promote
cell mobilisation in patients with type 2 diabetes.
To confirm the presence of a specific form of mobilopathy
affecting the subpopulation of CD34+NK1R+ HSPCs, we
investigated an independent cohort of 24 non-diabetic individ-
uals and 74 patients with type 2 diabetes (ESM Table 3 and
ESM Fig. 2). A multivariable analysis showed reduced PB
levels of CD34+NK1R+ HSPCs in the diabetic patients as
compared with non-diabetic individuals, even after adjust-
ment for BMI and medications that were significantly differ-
ent at univariate analysis.
Experimental study showing the inhibitory effect of type 2
diabetes on nociceptive-mediated HSPC mobilisation and
homing in mice with induced limb ischaemiaWe next con-
ducted studies to compare the abundance of nerve fibres in the
BM of Leprdb/db diabetic mice and non-diabetic controls and to
investigate the effect of experimental type 2 diabetes on
NK1R+ HSPC liberation as stimulated by peripheral ischaemia.
The abundance of neuronal fibres expressing the pan-neuronal
marker PGP9.5 and nociceptive SP-expressing nerves was mea-
sured in the marrow (Fig. 4a, b) and compact bone (Fig. 4c).
Morphometric analyses indicated that diabetes induces amarked
reduction in the density of both PGP9.5-positive fibres (Fig. 4d,
p<0.01 vs non-diabetic control) and SP-containing sensory
terminals (Fig. 4e, f, p<0.01 vs non-diabetic control).
Remarkable differences were observed in the tissue redis-
tribution of HSPC populations following LI in non-diabetic
mice compared with diabetic mice. In both groups, LI caused
an initial expansion of LSK-HSPCs in the BM, and this was
followed by a return to basal levels at 3–7 days post-LI and
then a second peak at 14 days (Fig. 5a, b). The subpopulation
of LSK-NK1R-HSPCs was reduced in the BM of non-
diabetic mice during the acute phase of LI, returning to basal
levels by day 7. In contrast, no change was observed in dia-
betic mice before and after LI (Fig. 5c, d). When looking at
cellular changes in PB, we observed a striking increase in
LSK-HSPCs and LSK-NK1R-HSPCs from day 1 to day 14
post-LI in non-diabetic mice, with this response being remark-
ably attenuated and delayed in diabetic mice (Fig. 5e–h,
p<0.01 vs non-diabetic mice). Additionally, the diabetic mice
manifested a reduction in the homing of LSK-HSPCs and
LSK-NK1R-HSPCs at the level of the ischaemic limbmuscle,
whereas no difference between groups was seen in the contra-
lateral muscle (Fig. 5i–l, p<0.01 vs non-diabetic mice).
We next investigated whether these deficits associate with
alterations of nociceptor-related mechanisms. To this aim, we
measured the levels of SP in BM supernatant fractions, PB














































































Fig. 4 Rarefaction of sensory fibres in the BM of diabetic mice. Immu-
nohistochemistry studies were carried out to compare the nerve fibre
density in the BM of mice with type 2 diabetes (T2DM) and respective
non-diabetic controls (ND). (a, b) Representative micrographs showing
the density of neuronal fibres expressing the pan-neuronal marker
PGP9.5 (a) and nociceptive fibres positive for SP (b) (scale bar,
20 μm). Arrows point to positive fibres. (c) Representative
immunofluorescence microscopy images of SP-positive fibres (arrows)
(scale bar, 50 μm). (d–f) Box and whisker graphs show morphometry
data. Boxes (black, non-diabetic; white, type 2 diabetes) are bordered at
the 5th and 95th percentiles of the variable with a median line at the 50th
percentile. Whiskers extend from the box to the upper and lower adjacent
values and are capped with an adjacent line. **p<0.01 vs non-diabetic
control; n=5 per group
2658 Diabetologia (2015) 58:2653–2662
m n o






















































































































0 1 3 7 14 21
Time post ischaemia (days)
Time post ischaemia (days)





















Pre-LI 3 days post-LI
Contralat Ischaemic






















































































































102 103 104 105
50 100 150 200 250
(x 1,000)
102 103 104 105
50 100 150 200 250
(x 1,000)
102 103 104 105



















































Fig. 5 Impairment of the
nociceptive mechanism is
associated with reduced liberation
and homing of stem cells in
diabetic mice submitted to
unilateral LI. (a–h) Flow cytometry
analyses showing the abundance of
LSK and LSK-NK1R cells in the
BM (a–d) and PB (e–h) of diabetic
(white bars) and non-diabetic
(black bars) mice, before and after
induction of unilateral LI. Data
expressed as percentage of
mononuclear cells (MNCs)
*p<0.05, **p<0.01 and
***p<0.001 vs time 0; ††p<0.01
and †††p<0.001 vs non-diabetic
control; n=5 per group. (i–l) Flow
cytometry analyses showing the
abundance of LSK (i, j) and
LSK-NK1R (k, l) cells in
ischaemic and contralateral limb
muscles of non-diabetic
(black boxes) and diabetic
(white boxes) mice at 3 days
post-LI compared with pre-LI.
***p<0.001 vs pre-LI; ††p<0.01
vs non-diabetic control; ‡‡p<0.01
vs contralateral; n=5 per group.
The gating strategy is shown in
(i) and (k). (m–o) Levels of SP in
the BM (m), PB (n) and ischaemic
muscles (o) of non-diabetic (black
boxes) and diabetic (white boxes)
mice before and after induction of
LI. *p<0.05, **p<0.01 and
***p<0.001 vs pre-LI; †p<0.05,
††p<0.01 and †††p<0.001 vs
non-diabetic control; n=5 per
group
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before and after LI. Two-way ANOVA detected an effect of
time (p<0.01) and group factor (p<0.01) on the levels of SP in
these different compartments; specifically, non-diabetic mice
manifested a positive gradient of SP between muscle, PB and
BM following LI, whereas this phenomenon was much atten-
uated in diabetic mice (Fig. 5m–o and ESM Fig. 3).
Since recruitment of LSK-NK1R-HSPCs has been shown
to be essential for post-ischaemic vasculogenesis [4], we
anticipated that the observed cellular defect may participate
in depressing the spontaneous recovery from ischaemia.
Consistently, the diabetic mice showed remarkable deficits
in limb blood-flow recovery (ESM Fig. 4a, b, p<0.01) and
reparative capillary angiogenesis (ESM Fig. 4c, d, p<0.001)
when compared with non-diabetic mice.
Clinical studies showing that dysfunctional nociception
contributes to defective G-CSF-induced mobilisation
Having shown that diabetes-induced nociceptive dysfunction
contributes to depressed HSPC release in ischaemia, we next
investigated the relation between pain, circulating levels of SP
and CD34+ HSPC mobilisation following direct stimulation
of BM with G-CSF.
A cohort of healthy volunteers received placebo or recom-
binant human G-CSF. Those receiving G-CSF were grouped
according to the level of pain (graded as pain score) induced
by the growth factor. Interestingly, individuals who experi-
enced moderate to severe bone or back pain showed a signif-
icantly greater increase in PB CD34+ HSPC counts than those
who reported no pain or mild pain (Fig. 6a, b). There was a
significant direct correlation between the pain score and the
increase in the number of CD34+ HSPCs induced by G-CSF
(r=0.36, p<0.02; Fig. 6c).
We also re-analysed data from a trial of BM stimulation with
human recombinant G-CSF in diabetic and non-diabetic indi-
viduals. Specifically, here we investigated the association of
HSPC mobilisation and pain perception. In the whole cohort,
the individuals who reported back or bone pain after G-CSF
administration showed a significantly higher increase in
PB CD34+ HSPCs than those reporting no pain (p<0.01,
Fig. 7a). Two-way ANOVA detected an inhibitory effect of
diabetes (p<0.0001) and an enhancing effect of pain
(p<0.01) on G-CSF-induced mobilisation, with no interaction
between factors. Furthermore, in diabetic patients, mobilisation
was completely abrogated in the absence of pain (Fig. 7a) and
there was no incremental effect of vascular complications on
mobilisation in comparison with diabetic patients without vas-
cular disease (Fig. 7b). To determine whether depressed noci-
ceptive signals may account for the reduced mobilisation of
HSPCs in diabetic patients, wemeasured PB SP concentrations
before and 24 h after G-CSF injection. Interestingly, G-CSF
administration caused an increase in SP levels in non-diabetic
individuals (p<0.05), with this response being abrogated in
diabetic patients (Fig. 7c). Additionally, in diabetic patients
with neuropathy and vascular complications, G-CSF stimula-
tion resulted in a decrease in PB SP levels (Fig. 7d, p<0.01 vs
non-diabetic individuals, p<0.05 vs diabetes without compli-
cations). We also found an association between changes in SP
concentrations and the degree of CD34+ HSPC mobilisation in
response to G-CSF. In fact, CD34+ HSPC mobilisation was
significantly higher in individuals showing an increase in SP
concentrations compared with those showing unchanged or
decreased SP levels (Fig. 7e, p<0.05).
Discussion
The results from this study represent a significant step
forward in the understanding of HSPC pathobiology and
its association with nociceptive dysfunction in patients
with diabetes. Although an alteration of sympathetic inner-
vation has been documented previously and suggested to
be the cause of diabetic mobilopathy [20, 25, 26], this is
the first demonstration of the degeneration of specific
nociceptive fibres in BM.
We previously demonstrated that tissue ischaemia triggers a
neuronal mechanism involving peripheral and central
nociceptors, leading to generation of an SP gradient that favours
Fig. 6 CD34+ cell mobilisation induced by G-CSF administration corre-
lates with pain score in non-diabetic individuals. (a) Changes (mean ±
SEM) in PB CD34+ cells of individuals given placebo (white bar, n=10)
or given G-CSF and classified as reporting no/mild bone/back pain (light
grey bar, n=15) or moderate/severe pain (dark grey bar, n=15); *p<0.05
for indicated comparison. (b) A pain score was computed as described in
the Methods section and plotted; *p<0.05 for indicated comparison. (c)
Linear correlation between the pain score and the degree of CD34+ cell
mobilisation in individuals who received G-CSF (r=0.36; p=0.016);
dashed lines represent the 95% CI and dotted line shows the grid line at
y=0
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the release of regenerative HSPCs from the BM. HSPCs are
recognised as contributing to post-ischaemic recovery through
paracrine promotion of reparative vascularisation and inhibition
of apoptosis [27]. Extending this concept, here we show for the
first time that diabetes remarkably blunts both the SP gradient
and NK1R-HSPC release upon induction of LI. The subpopu-
lation of nociceptive-sensitive NK1R-HSPCs is essential in
reparative processes as highlighted by studies in mice with
BM reconstitution by Nk1r-knockout cells [4]. Importantly,
the failure of NK1R-HSPCs to home to the ischaemic limb
muscle of diabetic mice translates to poor angiogenesis and
delayed blood-flow recovery. The newly described nociceptive
alteration is complementary to defects in resident vascular cells
and endothelial progenitor cells, all well acknowledged in ani-
mals and patients with diabetes.
Bone pain and back pain are the most common side effects
of G-CSF; here, we report for the first time that both activation
of pain and increased SP following G-CSF stimulation predict
the extent of HSPCmobilisation. Importantly, poor mobilisers
show a total lack of SP upregulation in their PB. Altogether,
these data lend strong support to the concept that nociception
plays a role in the regulation of HSPC mobilisation for vascu-
lar repair, whereas insensitivity to pain may jeopardise cellular
healing mechanisms in diabetes. Prevention and treatment of
neuropathy may become an integral component of new
strategies to enhance the mobilisation of HSPCs and halt
vascular damage, as we and others have shown [28, 29].
Conclusion and clinical perspectives Impaired nociception
is a typical feature of diabetic neuropathy, which is one of the
most common and disabling diabetic complications, affecting
millions of people worldwide. We herein provide evidence for
the existence of a nociceptive neuropathy in the BM of dia-
betic patients and animal models of diabetes and provide a
comprehensive overview of neurological alterations in the
diabetic BM. The translational nature of our work strongly
suggests that in both humans and in mice, neural control of
BM is affected by diabetes. The notion that sensory neuropathy
affects the BM and prevents release of reparative cells identifies
a hitherto neglected link between diabetic neuropathy and vas-
culopathy. Pursuing ways to bypass or overdrive the neurolog-
ical control of the BM niche is likely to uncover novel thera-
peutic strategies to counter diabetic vascular disease.
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